TECFIDERA

Peak

dimethyl fumarate

NDAORALCAPSULE, DELAYED RELEASE
Approved
Mar 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Clinical Trials (5)

NCT07258394Phase 3Recruiting

Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus

Started Jan 2026
NCT07138833Phase 4Not Yet Recruiting

A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS)

Started Sep 2025
NCT05767736N/AActive Not Recruiting

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Started Jun 2024
10,500 enrolled
Multiple Sclerosis
NCT05658484Phase 4Completed

A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

Started Jun 2023
60 enrolled
Multiple Sclerosis
NCT04756687N/ACompleted

Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera

Started Mar 2021
1,507 enrolled
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting

Loss of Exclusivity

LOE Date
Nov 16, 2035
118 months away
Patent Expiry
Nov 16, 2035

Patent Records (5)

Patent #ExpiryTypeUse Code
8399514
Feb 7, 2028
U-1384
10555993
Mar 13, 2035
U-3148
10994003
Mar 13, 2035
U-3148
10391160
Mar 13, 2035
U-3148
11007166
Nov 16, 2035
U-1384